According to the results, the PCR rate of neoadjuvant chemotherapies for breast cancer was related to the Ki-67 expression level (χ2 = 9.061, P = 0.003), lymph node metastasis (χ2 = 58.384, P = 0.000), and pTNM stage (χ2 = 18.772, P = 0.000), but unrelated to tumor size, Her-2 expressions, expressions of hormone receptors, attack of triple-negative breast cancer, and pathological molecular subtypes (P>0.05), as shown in Table 6. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.